Work

Intravesical Therapy – BCG and Beyond

Year: 2019

Type: article

Abstract: Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette–Guérin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.

Source: Bladder Cancer

DOI: 10.3233/blc-180198

Authors: H. Barton Grossman, Donald Lamm, Gottfrid Sjödahl, Michael O’Donnell, Noah Hahn, Ashish Kamat

Institutions: The University of Texas MD Anderson Cancer Center, University of Arizona College of Medicine- Phoenix, Lund University, Skåne University Hospital, University of Iowa, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2912909030

FWCI: 0.482

Cites: 37

Cited by: 3

Related to: 10